Breast Cancer Clinical Trial
— PYTHONOfficial title:
Preoperative Treatment of HR+/HER2+Breast Cancer With Pyrrolitinib Combined With Trastuzumab and AI Efficacy and Safety of: a Single Arm Multicenter Phase II Exploratory Study
Research topic Preoperative efficacy and safety of pyrrolitinib combined with trastuzumab and AI in the treatment of HR+/HER2+breast cancer Overall: A single arm multicenter phase II exploratory study。Subjects HR+/HER2+breast cancer patients in stage Ⅱ~Ⅲ A。
Status | Recruiting |
Enrollment | 48 |
Est. completion date | September 30, 2025 |
Est. primary completion date | March 30, 2024 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Female initial treatment patients aged = 18 years and = 75 years old - ECOG score 0-1 - Stage II-IIIA invasive breast cancer, diameter = 20mm - HER2 positive (IHC score of 3+, or 2+and ISH test positive) - ER>10% - Doctors choose to use letrozole/anastrozole for endocrine therapy - The definition of menopause includes any of the following: (Previous bilateral oophorectomy; Age)= 60 years old; Age<60 years old and without chemotherapy, tamoxifen, toremifen, or ovarian suppressionUnder normal conditions, menopause lasts for = 12 months, and follicle stimulating hormone (FSH) and estradiol are within the postmenopausal range;If receiving tamoxifen or toremifen and age<60 years, FSH and plasma estradiolWithin the postmenopausal range) - Left ventricular ejection fraction (LVEF) = 50% - 12 lead electrocardiogram: QT interval (QTcF) corrected by Fridericia method for females<470ms; - The functional level of the main organs must meet the following requirements: blood routine: ANC = 1.5 × 109/L; PLT=90 × 109/L; Hb=90 g/L;Blood biochemistry: TBIL = 2.5 × ULN; ALT and AST = 2.5 × ULN; BUN and Cr = 1.5 × ULN; - For female subjects who have not undergone menopause or surgical sterilization, during the treatment period and during the study treatment - Agree to abstain or use effective contraceptive methods for at least 2 months after the next administration; .Volunteer to join this study, sign informed consent, have good compliance, and be willing to cooperate with follow-up. Exclusion Criteria: - Stage IIIB-IV or inflammatory breast cancer - Metastatic tumor - Previous or concurrent malignant tumors, whose natural history or treatment may interfere with the safety of the research protocol Patients evaluated for sex or efficacy are not eligible to participate in this trial, but basal or squamous cell skin Except for cancer, cervical cancer in situ or bladder cancer, or the subject has no disease (other cancer) to survive At least 5 years. - Active infections that require systemic treatment - Has used any medication in this study within 14 days prior to enrollment - Major surgery (excluding biopsy) performed within 14 days before enrollment - Gastrointestinal dysfunction or diseases may seriously affect the absorption of drugs in this study (such as ulcerative Disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection) or Severe damage to the ability to swallow capsules/tablets - Known history of myelodysplastic syndrome or acute myeloid leukemia - Have a history of abdominal fistula, gastrointestinal perforation, or abdominal abscess within 28 days - Have any history of cerebrovascular accident (CVA) or transient ischemic attack within 12 months - Within 6 years, there is a history of acute coronary syndrome (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty or stent implantation) or symptomatic pericarditis |
Country | Name | City | State |
---|---|---|---|
China | Tianjin Cancer Hospital | Tianjin | Tianjin |
Lead Sponsor | Collaborator |
---|---|
Tianjin Medical University Cancer Institute and Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Follow up on postoperative pathological reports for evaluation for tumor residual load(RCB) | Follow up on postoperative pathological reports for evaluation rely on residual cancer burden | 18weeks | |
Other | Follow up on postoperative pathological reports for evaluation for breast retention rate | Follow up on postoperative pathological reports for evaluation rely on Number of all breast conserving patients | 18weeks | |
Primary | Follow up on postoperative pathological reports for evaluation for Pathological complete response rate (tpCR: ypT0-is/ypN0) | Follow up on postoperative pathological reports for evaluation rely onMiller&Payne principles | 18weeks | |
Secondary | Follow up on postoperative pathological reports for evaluation for Optimal overall response rate (BORR) | Follow up on postoperative pathological reports for evaluation rely onMiller&Payne principles | 18weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |